Thermo Fisher Scientific Unveils Next-Generation Innovations at ASMS 2026
Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, recently announced groundbreaking advancements in mass spectrometry technology during the American Society for Mass Spectrometry (ASMS) Conference. The unveiling of the Thermo Scientific™ Orbitrap™ Tribrid™ Apex and the Thermo Scientific™ Orbitrap™ Excedion™ mass spectrometers signifies a pivotal moment in the acceleration of drug discovery and the development of new therapies.
1. Meeting Increasing Demands in Scientific Discovery
As scientific research evolves to encompass more intricate applications—including advanced proteomics, multiomics, biologics, and genetic medicines—researchers are under mounting pressure to produce high-quality data swiftly. The latest innovations from Thermo Fisher aim to meet these challenges head-on. By integrating high-performance instrumentation with AI-enabled software, these new products provide scalable solutions to expedite the drug development process, making it easier for scientists to identify disease mechanisms and validate therapeutic targets.
“Innovation in molecular analysis technologies is helping our customers advance scientific discovery and generate deeper biological insights at an unprecedented pace,” said Marc N. Casper, chairman and CEO of Thermo Fisher Scientific. “By combining next-generation Orbitrap platforms with AI-driven analytics, we are now helping scientists transform increasingly complex data into actionable insights to further accelerate the path from discovery to precision therapies.”
2. Advancing Early Discovery with Greater Depth and Versatility
The Thermo Scientific Orbitrap Tribrid Apex Mass Spectrometer leverages the proven Orbitrap Tribrid Technology, enabling comprehensive analysis of complex biological samples within a single platform.
Notable features of the Orbitrap Tribrid Apex include:
- Five Times Greater Sensitivity: This allows researchers to study challenging biological samples with unmatched clarity.
- Up to 100% Sequence Coverage: Achieved in a single experiment, significantly enhancing data quality.
- Speed: Results are delivered up to four times faster than previous-generation instruments.
These advancements empower scientists to uncover underlying disease mechanisms earlier and identify therapeutic targets sooner, particularly in critical fields such as oncology and neurodegeneration. The Orbitrap Tribrid Apex is versatile, supporting over 300 areas of research and translating discoveries into accelerated drug development.
Dr. Neil Kelleher, director of the Proteomics Center of Excellence at Northwestern University, praised the instrument, stating, “The Orbitrap Tribrid Apex mass spectrometer is the best proteoform sequencer I’ve seen in my 25 years of translational research. It opens an exciting frontier for obtaining deep sequence coverage of proteoforms with unparalleled sensitivity, and these capabilities will enable us to understand complex diseases like never before.”
3. Enabling More Confident Decisions in Drug Development
As research transitions from discovery to development, the emphasis shifts from biological understanding to obtaining robust data necessary for regulatory compliance. The Thermo Scientific Orbitrap Excedion Mass Spectrometer is specifically designed to mitigate risks in complex drug development pipelines.
Key advantages of the Orbitrap Excedion include:
- Increased Detection Capabilities: It can detect three to five times more compounds in intricate samples, yielding more comprehensive data.
- Regulatory Readiness: The system provides data that supports safety, efficacy, and dosing decisions, crucial for meeting regulatory requirements.
- Earlier Signal Detection: The platform facilitates the early identification of low-abundance molecules, aiding in the recognition of critical molecular signals.
These capabilities are instrumental in reducing downstream risks and expediting the time to market for new therapies.
4. Connecting Discovery to Population-Scale Insight
Thermo Fisher’s innovations are part of a broader strategy to link biological discovery with large-scale validation. At ASMS, the company is also showcasing its Olink® proteomics platform, which allows for high-specificity protein analysis at a population scale, complementing Orbitrap-based workflows. This integrated approach is being utilized in significant initiatives, such as PRECISE, a biobank program aiming to identify biomarkers associated with aging and metabolic diseases.
Recent acquisitions, including MSAID and Proteinaceous, enhance Thermo Fisher’s proteomics ecosystem by incorporating AI and machine learning capabilities, enabling scientists to analyze complex datasets with greater speed and accuracy.
5. Conclusion: A Look Ahead
Thermo Fisher Scientific will exhibit these innovative products at booth 801 during the ASMS 2026 annual conference in San Diego from June 1-4, 2026. With their continued commitment to advancing scientific discovery, Thermo Fisher remains at the forefront of molecular analysis technologies that are set to revolutionize drug development and therapeutic advancements.
With annual revenues exceeding $45 billion, Thermo Fisher Scientific maintains its mission to enable customers to create a healthier, cleaner, and safer world through innovative technologies and services. For more information about their offerings and the ASMS conference, visit www.thermofisher.com/ASMS.
